ClinicalTrials.Veeva

Menu

Machado-Joseph Disease in Israel

Clalit Health Services logo

Clalit Health Services

Status

Unknown

Conditions

Spinocerebellar Ataxia 3

Study type

Observational

Funder types

Other

Identifiers

NCT02175290
MMC140006CTIL

Details and patient eligibility

About

Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA-3) is the most common dominant ataxia. The genetic cause of this late-onset degenerative disorder is the expansion of a (CAG)n tract located in the exonic region of the ATXN3 gene. In 1994 the first case of MJD among the Yemenite Jewish subpopulation living in Israel was published. The puropse of this study is to describe the clinical phenotype and genotype of the Yemenite Jewish subpopulation with MJD living in Israel

Enrollment

250 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Spinocerebellar Ataxia 3 Yemenite Jews patients

Exclusion criteria

  • All others

Trial design

250 participants in 1 patient group

Spinocerebellar Ataxia 3 Yemenite Jews patients

Trial contacts and locations

1

Loading...

Central trial contact

Carlos R Gordon, MD;DSc; Roy Zaltzman, MD;PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems